How Sound Waves Are Helping Patients Overcome Severe Addiction

2026-08-14 bio

Morgantown, Friday, 14 August 2026.
A groundbreaking, noninvasive ultrasound therapy reduces severe drug cravings by over 90% in just 20 minutes, offering a major surgical-free advancement for treating complex addiction.

A Healthtech Milestone in Addiction Medicine

This revolutionary development falls squarely within the sectors of healthtech and advanced neuromodulation medicine [1][2]. Led by Dr. Ali Rezai, a pioneering neurosurgeon and executive chair of the West Virginia University (WVU) Rockefeller Neuroscience Institute based in West Virginia, this technology offers a noninvasive alternative to highly invasive deep brain stimulation (DBS) surgeries [1]. While traditional DBS surgeries can take up to 16 hours and require opening the skull to implant electrodes, this new focused ultrasound (FUS) therapy is completed in just 20 minutes, allowing patients to be discharged on the very same day [1]. This transition from scalpel-based surgery to sound-wave therapeutics represents a massive paradigm shift for clinical researchers and healthcare systems seeking to manage the escalating substance abuse crisis [1][2].

How Focused Ultrasound Resets Neural Pathways

The procedure works by utilizing low-intensity focused ultrasound (LIFU) to target the nucleus accumbens, a deep-brain structure located approximately 8 centimeters from the top of the head [1]. This specific region is heavily involved in the brain’s reward system and becomes severely dysregulated and hypersensitized during chronic addiction, constantly seeking dopamine highs [1]. By sending highly precise, noninvasive energy beams through the skull without damaging surrounding tissue, the ultrasound acts as a non-pharmacologic neuromodulation tool that essentially ‘reboots’ these hyperactive pathways [1][2]. This targeted approach allows clinicians to alter nervous activity and suppress intense drug cravings directly at their neurological source, achieving a feat that transcranial magnetic stimulation cannot reach due to the depth of the nucleus accumbens [1].

The Science of Resetting the Brain’s Reward System

The primary benefit of this healthtech innovation is its rapid and dramatic reduction of drug cravings, which often subside while the patient is still on the treatment table [1]. In clinical trials conducted by the WVU team, the first 20 participants reported a greater than 90% reduction in self-reported cravings alongside an 80% reduction in positive urine drug tests [1]. Out of the 47 total participants who have undergone the procedure at WVU as of August 2026, this initial cohort represents approximately 42.553% of the treated group [1]. Additionally, independent academic discussions and related studies have highlighted a similar 91% average reduction in cue-induced opioid cravings following targeted focused ultrasound neuromodulation [3]. For patients who have failed multiple traditional rehabilitation attempts, this rapid suppression of cravings provides a critical window of sobriety to rebuild their lives [1].

Clinical Trials and Safety Considerations

Despite the immense promise of the therapy, the path to clinical approval has faced safety hurdles. In July 2025, a 44-year-old volunteer in the WVU trial suffered minor brain hemorrhages in and around the nucleus accumbens one month after his procedure, prompting an eight-month trial suspension while researchers consulted with the Food and Drug Administration (FDA) and device manufacturer Insightec [1]. This incident sparked intense safety debates and letters to the editor among global neurological experts regarding adverse events in late 2025 [2]. However, the exploratory trials have resumed, and the global footprint of focused ultrasound research continues to expand [2]. Active clinical trials for addiction are currently underway globally, including alcohol use disorder studies in Toronto, Canada, Virginia Tech, and San Francisco, California, alongside food addiction trials at the University of Utah and WVU [2][6].

The Path to Portability and Future Outlook

Looking ahead, the WVU Rockefeller Neuroscience Institute is designing a portable, non-magnetic resonance imaging (MRI) device that resembles a salon hair dryer [1]. This planned advancement aims to democratize access to the treatment, allowing trained medical technicians rather than specialized neurosurgeons to administer the therapy in local clinics [1]. For patients like Erin, a 45-year-old participant who underwent the active procedure in January 2025 after a placebo phase failed, the treatment has been life-changing [1]. Following her recovery, Erin relocated back to Vermont in May 2026, where she now works in a family antiques business and lives craving-free [1]. As researchers gather at global summits like the Focused Ultrasound in Psychiatry Symposium (FUS PULSE) to share data, this noninvasive approach is poised to reshape the future of psychiatric and addiction medicine [4].

Bronnen

neuromodulation focused ultrasound